key: cord-0887735-rbd9995l
authors: Carlson, F. Roy; Bosukonda, Dattatreyamurty; Keck, Peter C.; Carlson, William D.
title: MULTIORGAN DAMAGE IN PATIENTS WITH COVID-19: IS THE TGF-β /BMP PATHWAY THE MISSING LINK?
date: 2020-09-22
journal: JACC Basic Transl Sci
DOI: 10.1016/j.jacbts.2020.09.003
sha: 768b024dd7f956f855e38ec23731be04cebb82dc
doc_id: 887735
cord_uid: rbd9995l

[Figure: see text]

COVID-19 is a viral infection that attacks the lungs, leading to Severe Acute Respiratory Syndrome (SARS) with a resultant high mortality. The highest mortality is seen in patients with multiorgan injuries including the heart, the kidney and the liver (1). These derangements speak to a systemic disorder, and an effective treatment will need to address the multiplicity of effects.

Recent data show that there are long-term deleterious effects from COVID-19. In one study, using cardiac magnetic resonance imaging, 70% of patients with mild disease from COVID-19 had evidence of cardiac dysfunction and significant cardiac fibrosis up to 2 months after discharge from the hospital. Developing a treatment to stop the virus from replicating will be critical to control this pandemic, but treatments for multiorgan involvement will be essential in treating the widespread damage to the lungs, the heart, the kidneys and other organs. With the highest mortality in these patients thought to be caused by rapid progression of pulmonary fibrosis, an agent that could slow the progression of fibrosis, or possibly reverse the fibrosis and restore function, could be a significant advance in the treatment of this devastating disease, for which we currently have limited treatment options. An agent that could prevent or reverse fibrosis in multiple organs could prevent patients from developing disabling chronic conditions. While antiviral drugs and vaccines are being developed, the current treatment for COVID-19 SARS is supportive therapy with intubation and ventilator support. The underlying pathology of this process is complex and incompletely characterized, but involves inflammation, apoptosis and fibrosis (2) . The patients with the most serious respiratory distress are characterized by severe pulmonary fibrosis for which we have no current therapy.

The cardiac injury associated with COVID-19 has yet to be characterized in detail, but it is known that it involves direct injury to the myocardium leading to left ventricular dysfunction.

There is now evidence of permanent damage to cardiac function in patients who have recovered from COVID-19. Similar to heart injury, the kidney injury that occurs with COVID-19 is also associated with higher mortality. The injury is thought to result from the virus' direct toxicity to the cardiac or kidney cells, resulting in apoptosis and a cytokine release phenomenon further injuring organ cells and leading to fibrosis and loss of function. Since ACE and ACE2 are known to be expressed in cardiac and renal tissue, it is likely that COVID-19 binds to these extracellular proteins and stimulates TGF-β through the same Smad3 activation as in the pulmonary tissue.

After the SARS epidemic in 2003 there were a number of investigations into the mechanism of organ damage produced by that viral infection. It emerged that the virus had a protein on its surface that attached to the Angiotensin Converting Enzyme 2 (ACE2) receptor in lung epithelial cells. This attachment was followed by internalization and intracellular replication of the virus.

Subsequently Transforming Growth Factor-β (TGF-β) signaling was activated through both the canonical and the non-canonical signaling pathways (3, 4) . The canonical pathway was activated by a nucleocapsid protein (Np) interacting with Smad3 ( Fig. 1a) , and the non-canonical pathway was activated by a papain-like protein thus upregulating TGF-β (Fig. 1b) . Mechanism. BMP-7 and TGF-β1 bind to distinct type II receptors that form complexes of specific type I serine-threonine kinase receptors. BMP-7 binds specifically to activin-like kinase (ALK)-3 and ALK-6 receptors, whereas TGF-β1 binds to the ALK-5 receptor. The complexes trigger the initiation of intracellular signal streams mediated by Smad proteins. BMP-7 phosphorylates RSmads 1, 5, and 8, whereas TGF-β1 activates RSmads 2 and 3. Smad4 acts as a partner to facilitate translocation of the activated RSmads into the nucleus. The translocated heteromeric complex involving RSmads 2 and 3 modulates pro-fibrotic genes, promoting the differentiation of fibroblasts to myofibroblasts such as α-smooth muscle actin (α-SMA), inducing EMT, and enhancing the deposition of collagen. Similarly, upon activation by exogenous BMP-7, Smad1/5/8 complex with Smad4, translocates into the nucleus and blocks the nuclear accumulation of Smad3 and thereby TGF-β1 action. This Phosphorylation of Smad 1/5/8 by BMP-7 results in the transcription of target genes that oppose the fibrogenic effects induced by TGF-β/Smad 2/3 signaling. At physiologic concentrations, Smad6 appears to inhibit BMP signaling by interacting with BMP type I receptors and Smad7 inhibits TGF-β/activin signaling by interaction with TGF-β/activin type I receptors, which suggests that the principal functions of Smad6 and Smad7 are to regulate the BMP or TGF-β/activin pathways, respectively. Moreover, Smad7 suppresses fibrosis by altering TGF-β/Smad3-regulated microRNAs.

The flip side of the TGF-β signaling is the BMP signaling pathway (Fig 2) . Study of the BMP pathway has shown that activation of this pathway counters the deleterious effects of TGF-β, blocking inflammation, apoptosis and reversing fibrosis. Recently, there has been an interest in harnessing the BMP pathway to reverse the deleterious effects of TGF-β with a BMP agonist.

In 

The osteogenic activity appears to be mediated through the ALK6 type I receptor. Thus, any therapeutic agent employing the BMP signaling pathway necessarily needs to have no or minimal affinity for the ALK6 type I receptor while retaining the anti-inflammatory, antiapoptotic and anti-fibrotic properties of BMP-7. There is a class of compounds that have been developed to activate the BMP pathway, called BMP mimetics. These compounds do not have the aforementioned limitations, and meet the criteria for a potential therapeutic (5) . They are resistant to inhibition by natural BMP inhibitory proteins such as follistatin, noggin, gremlin and chordin. These BMP mimetics have been shown to protect cardiac and renal tissue from injury arising from a variety of agents, by reversing fibrosis and restoring function. Because available evidence suggests that the triad of pathologic mechanisms of inflammation, apoptosis and fibrosis promote high mortality in COVID19 SARS patients, these BMP mimetics could be an effective agent to treat the associated multiorgan injury.

Activation of the BMP signaling pathway is a natural and effective means of modulating the deleterious effects of TGF-β by antagonizing TGF-β signaling. Taking this TGF-β signaling aspect of the disease into account likely provides a major treatment opportunity for reducing mortality and an even more significant opportunity to reducing serious long-term morbidity.

J o u r n a l P r e -p r o o f

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Multiple organ infection and the pathogenesis of SARS

Severe Acute Respiratory Syndrom-associated Coronavirus Nucleocapsid Protein Interacts with Smad3 and Modulates Transforming Growth Factor-B signaling

SARS coronavirus papain-like protease upregulates the collagen expression through non-Smad TGFb signaling

Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis